APA (7th ed.) Citation

Durie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., . . . Dispenzieri, A. (2017). Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial. The Lancet (British edition), 389(10068), 519-527. https://doi.org/10.1016/S0140-6736(16)31594-X

Chicago Style (17th ed.) Citation

Durie, Brian G M., et al. "Bortezomib with Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone in Patients with Newly Diagnosed Myeloma Without Intent for Immediate Autologous Stem-cell Transplant (SWOG S0777): A Randomised, Open-label, Phase 3 Trial." The Lancet (British Edition) 389, no. 10068 (2017): 519-527. https://doi.org/10.1016/S0140-6736(16)31594-X.

MLA (9th ed.) Citation

Durie, Brian G M., et al. "Bortezomib with Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone in Patients with Newly Diagnosed Myeloma Without Intent for Immediate Autologous Stem-cell Transplant (SWOG S0777): A Randomised, Open-label, Phase 3 Trial." The Lancet (British Edition), vol. 389, no. 10068, 2017, pp. 519-527, https://doi.org/10.1016/S0140-6736(16)31594-X.